{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Ethanol", "Fucoidan", "Gastro-protective", "Inflammation", "NLRP3", "Pyroptosis", "Ulcer"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37201406", "DateCompleted": {"Year": "2023", "Month": "06", "Day": "16"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.1016/j.intimp.2023.110335", "S1567-5769(23)00658-6"], "Journal": {"ISSN": "1878-1705", "JournalIssue": {"Volume": "120", "PubDate": {"Year": "2023", "Month": "Jul"}}, "Title": "International immunopharmacology", "ISOAbbreviation": "Int Immunopharmacol"}, "ArticleTitle": "Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis.", "Pagination": {"StartPage": "110335", "MedlinePgn": "110335"}, "Abstract": {"AbstractText": ["This study aimed to elucidate the gastro-protective effect of fucoidan against ethanol-induced gastric ulcer mediated via NLRP3-induced pyroptosis as an underlying mechanism, not yet assessed in prior research. Forty-eight male Albino mice were divided into six groups: Group I (normal control), group II (Ulcer/ethanol control), group III (Omeprazole\u00a0+\u00a0ethanol), group IV (fucoidan 25\u00a0mg\u00a0+\u00a0ethanol), group V (fucoidan 50\u00a0mg\u00a0+\u00a0ethanol) and group VI (fucoidan only). Fucoidan was administered orally for seven consecutive days followed by ulcer induction by a single oral dose of ethanol. Using colorimetric analysis, ELISA, qRT-PCR, histological assessment, and immunohistochemical studies, the results revealed that ethanol-induced ulcer exhibited an ulcer score of 42.5\u00a0\u00b1\u00a05.1 and a significant increase (p\u00a0<\u00a00.05) in malondialdehyde (MDA), nuclear factor kappa B (NF-\u03baB), and interleukin 6 (IL-6) with a significant decrease in the gastro-protective mediators, prostaglandin E2 (PGE2), superoxide dismutase (SOD) and glutathione (GSH), accompanied with an increase in NLRP3, interleukin 1\u03b2 (IL-1\u03b2), interleukin 18 (IL-18), caspase 1, caspase 11, gasdermin D, and toll-like receptor 4 (TLR4), compared with the normal control. Pre-treatment with fucoidan showed a comparable result with omeprazole. Additionally, pre-treatments elevated the levels of the gastro-protective mediators and lessened oxidative stress, relative to the positive control findings. Conclusively, fucoidan has a promising gastro-protective role by inhibiting inflammation and pyroptosis."], "CopyrightInformation": "Copyright \u00a9 2023 Elsevier B.V. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biochemistry Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt."}], "LastName": "Selim", "ForeName": "Hend Mostafa", "Initials": "HM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt."}], "LastName": "Negm", "ForeName": "Walaa A", "Initials": "WA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 4545, Saudi Arabia."}], "LastName": "Hawwal", "ForeName": "Mohammed F", "Initials": "MF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Hussein", "ForeName": "Ismail A", "Initials": "IA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt."}], "LastName": "Elekhnawy", "ForeName": "Engy", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Bioprocess Engineering, Rheinland-Pf\u00e4lzische Technische Universit\u00e4t Kaiserslautern-Landau, Gottlieb-Daimler-Stra\u00dfe 49, 67663 Kaiserslautern, Germany."}], "LastName": "Ulber", "ForeName": "Roland", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt; Institute of Bioprocess Engineering, Rheinland-Pf\u00e4lzische Technische Universit\u00e4t Kaiserslautern-Landau, Gottlieb-Daimler-Stra\u00dfe 49, 67663 Kaiserslautern, Germany. Electronic address: ahmed.zayed1@pharm.tanta.edu.eg."}], "LastName": "Zayed", "ForeName": "Ahmed", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Int Immunopharmacol", "NlmUniqueID": "100965259", "ISSNLinking": "1567-5769"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"RegistryNumber": "9072-19-9", "NameOfSubstance": "fucoidan"}, {"RegistryNumber": "GAN16C9B8O", "NameOfSubstance": "Glutathione"}, {"RegistryNumber": "KG60484QX9", "NameOfSubstance": "Omeprazole"}, {"RegistryNumber": "3K9958V90M", "NameOfSubstance": "Ethanol"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["chemically induced", "drug therapy", "pathology"], "DescriptorName": "Stomach Ulcer"}, {"QualifierName": ["metabolism"], "DescriptorName": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ulcer"}, {"QualifierName": [], "DescriptorName": "Pyroptosis"}, {"QualifierName": [], "DescriptorName": "Gastric Mucosa"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["metabolism"], "DescriptorName": "Inflammation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glutathione"}, {"QualifierName": ["therapeutic use", "pharmacology"], "DescriptorName": "Omeprazole"}, {"QualifierName": ["metabolism"], "DescriptorName": "Ethanol"}, {"QualifierName": ["metabolism"], "DescriptorName": "NF-kappa B"}], "CoiStatement": "Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2023", "Month": "2", "Day": "20"}, {"Year": "2023", "Month": "4", "Day": "28"}, {"Year": "2023", "Month": "5", "Day": "10"}, {"Year": "2023", "Month": "6", "Day": "16", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "19", "Hour": "1", "Minute": "4"}, {"Year": "2023", "Month": "5", "Day": "18", "Hour": "18", "Minute": "7"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37201406", "10.1016/j.intimp.2023.110335", "S1567-5769(23)00658-6"]}}], "PubmedBookArticle": []}